Assessment of the potential value of combining western medicine therapies with traditional chinese medicine in the treatment of COVID-19: Mechanistic perspectives.

Publisher: IOS Press Country of Publication: Netherlands NLM ID: 9314590 Publication Model: Print Cited Medium: Internet ISSN: 1878-7401 (Electronic) Linking ISSN: 09287329 NLM ISO Abbreviation: Technol Health Care Subsets: MEDLINE

Publication: Amsterdam : IOS Press
Original Publication: Amsterdam ; New York : Elsevier, c1993-

COVID-19* ; Drugs, Chinese Herbal*/therapeutic use; Humans ; Medicine, Chinese Traditional/methods ; COVID-19 Drug Treatment ; COVID-19 Serotherapy

Background: The pandemic caused by the novel coronavirus disease (COVID-19) since early 2020 is one of the most significant global health issues in history. Although there is currently no specific treatment for COVID-19, researchers have provided a whole array of potential treatments, both from the Western medicine approach, which is molecular target and pathogenesis based, and from the traditional Chinese medicine (TCM) approach, which is based on the exposure to toxins/pathogens and the balance of the body to combat them for recovery.
Objective: The aim of this research is to find combinations of Western medicine and TCM that may offer better therapeutic efficacy synergystically with a better adverse events profile. The findings of the research may provide a new insight in the development of the treatment of COVID-19.
Methods: From the Western medicine perspective, drugs target the mechanisms of viral infection, including the stages of viral entry (Arbidol, Camostat Mesylate, Convalescent Plasma therapy) and viral replication (Lopinavir/Ritonavir, Redemsivir, Ribavirin). Additional therapies target host defenses, preventing cytokine storms (Tocilizumab) and stimulating the immune system (Interferons). On the other hand, TCM also proposed a number of treatment methods for COVID-19 with new scientific approaches identifying their antiviral and immunomodulatory activities. The novel combination of Western medicine and TCM can be proposed by analyzing their respective molecular targets.
Results: Although TCM is not generally accepted in the Western community because of the general lack of knowledge on their detailed mechanisms, studies and clinical trials suggest that TCM could be beneficial in combating COVID-19.
Conclusion: Based on the principle of combining TCM and Western medicine, two combinations are tested effective in clinical trials, and three possible combinations that might be effective are proposed in the paper.

J Tradit Chin Med. 2020 Jun;40(3):467-472. (PMID: 32506862)
Thorax. 2004 May;59(5):414-20. (PMID: 15115870)
Lancet. 2020 Oct 3;396(10256):953-954. (PMID: 33010833)
Lancet. 2020 May 16;395(10236):1569-1578. (PMID: 32423584)
Thorax. 2004 Mar;59(3):252-6. (PMID: 14985565)
J Pathol. 2004 Jun;203(2):631-7. (PMID: 15141377)
Ann Palliat Med. 2020 Sep;9(5):3235-3248. (PMID: 32954754)
JAMA. 2020 May 12;323(18):1824-1836. (PMID: 32282022)
Clin Microbiol Infect. 2020 Jul;26(7):917-921. (PMID: 32344167)
Ther Clin Risk Manag. 2008 Oct;4(5):1023-33. (PMID: 19209283)
Sichuan Da Xue Xue Bao Yi Xue Ban. 2014 Sep;45(5):863-5. (PMID: 25341356)
Integr Med Res. 2020 Sep;9(3):100489. (PMID: 32874913)
BMJ. 2020 May 14;369:m1849. (PMID: 32409561)
N Engl J Med. 2020 May 7;382(19):1787-1799. (PMID: 32187464)
Antiviral Res. 2014 Jul;107:84-94. (PMID: 24769245)
Travel Med Infect Dis. 2020 May - Jun;35:101647. (PMID: 32247927)
Open Forum Infect Dis. 2020 Mar 23;7(4):ofaa105. (PMID: 32284951)
J Virol. 2020 Nov 9;94(23):. (PMID: 32938761)
Complement Ther Med. 2003 Jun;11(2):118-22. (PMID: 12801499)
Oncogene. 1998 Aug 20;17(7):913-8. (PMID: 9780008)
Cell Res. 2020 Mar;30(3):269-271. (PMID: 32020029)
Pharmacol Res. 2020 Jun;156:104761. (PMID: 32205232)
Comb Chem High Throughput Screen. 2021;24(4):591-597. (PMID: 32807047)
Viruses. 2021 Apr 02;13(4):. (PMID: 33918301)
Med. 2020 Dec 18;1(1):105-113.e4. (PMID: 32838353)
J Med Chem. 2020 Nov 25;63(22):13205-13227. (PMID: 32845145)
J Pharmacol Sci. 2004 Nov;96(3):229-45. (PMID: 15539763)
Chin Herb Med. 2020 Oct;12(4):349-358. (PMID: 32963508)
J Ethnopharmacol. 2012 Apr 10;140(3):469-75. (PMID: 22330011)
Evid Based Complement Alternat Med. 2013;2013:208349. (PMID: 24194779)
Chin J Nat Med. 2020 Dec;18(12):881-889. (PMID: 33357718)
Emerg Infect Dis. 2004 Feb;10(2):317-9. (PMID: 15030704)
Arch Pharm Res. 2020 Apr;43(4):433-448. (PMID: 32219716)
Phytomedicine. 2021 May;85:153242. (PMID: 33867046)
Endocr Metab Immune Disord Drug Targets. 2020;20(6):807-811. (PMID: 32338224)
Eur J Pharmacol. 2020 Sep 15;883:173372. (PMID: 32682787)
Chin Med. 2020 Sep 3;15:94. (PMID: 32905189)
Immunity. 2020 Jul 14;53(1):19-25. (PMID: 32610079)
Sci Rep. 2021 Apr 13;11(1):8059. (PMID: 33850184)
Cell Discov. 2020 May 2;6:28. (PMID: 32373347)
Antiviral Res. 2015 Apr;116:76-84. (PMID: 25666761)
Chin Med J (Engl). 2020 May 5;133(9):1087-1095. (PMID: 32358325)
Zhongguo Zhong Yao Za Zhi. 2020 May;45(10):2249-2256. (PMID: 32495577)
Zhongguo Zhong Yao Za Zhi. 2017 Mar;42(5):836-843. (PMID: 28994522)
Pharmacol Res. 2020 Aug;158:104939. (PMID: 32445956)
Cureus. 2020 May 24;12(5):e8260. (PMID: 32596078)
Virol J. 2005 Aug 22;2:69. (PMID: 16115318)
Nat Commun. 2020 Jan 10;11(1):222. (PMID: 31924756)
Nat Rev Microbiol. 2021 Mar;19(3):141-154. (PMID: 33024307)
Arthritis Rheum. 2005 Mar;52(3):818-25. (PMID: 15751095)
Nature. 2018 Sep;561(7724):448-450. (PMID: 30258149)
Phytother Res. 2016 Aug;30(8):1207-18. (PMID: 27188216)
Proc Natl Acad Sci U S A. 2020 May 19;117(20):10970-10975. (PMID: 32350134)
Molecules. 2020 Mar 30;25(7):. (PMID: 32235534)
J Med Chem. 1988 Feb;31(2):283-4. (PMID: 3339601)
Eur J Integr Med. 2021 Jan;41:101251. (PMID: 33204368)
Pharmacol Res. 2020 Oct;160:105036. (PMID: 32565309)
Lancet. 2003 Jun 14;361(9374):2045-6. (PMID: 12814717)
Antiviral Res. 2007 May;74(2):92-101. (PMID: 16730806)
Biomed Pharmacother. 2021 May;137:111310. (PMID: 33761591)
Int J Infect Dis. 2020 Sep;98:334-346. (PMID: 32634589)
J Infect Dis. 2004 Apr 1;189(7):1164-7. (PMID: 15031783)
PLoS One. 2015 Feb 06;10(2):e0117602. (PMID: 25658356)
Cell. 2020 Apr 16;181(2):271-280.e8. (PMID: 32142651)
Int Immunopharmacol. 2020 Nov;88:106924. (PMID: 32877828)
J Med Chem. 2005 Feb 24;48(4):1256-9. (PMID: 15715493)
BMC Infect Dis. 2017 Feb 13;17(1):144. (PMID: 28193191)
ScientificWorldJournal. 2015;2015:731765. (PMID: 25654135)
J Med Virol. 2020 May;92(5):479-490. (PMID: 32052466)

Keywords: COVID-19; SARS-CoV-2; therapies; traditional Chinese medicine

0 (Drugs, Chinese Herbal)

Date Created: 20230411 Date Completed: 20230502 Latest Revision: 20240930

20240930

PMC10200170

10.3233/THC-236015

37038790